Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume -, Issue -, Pages 104195
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.critrevonc.2023.104195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
- (2023) Itziar Otano et al. Nature Reviews Clinical Oncology
- Immunotherapy-based combinations in metastatic NSCLC
- (2023) Aakash Desai et al. CANCER TREATMENT REVIEWS
- Sponsorship bias in oncology cost effectiveness analysis
- (2023) Ting Zhou et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Lung cancer immunotherapy: progress, pitfalls, and promises
- (2023) Aritraa Lahiri et al. Molecular Cancer
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050
- (2023) Simiao Chen et al. JAMA Oncology
- Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
- (2023) Lisa May Ling Tachiki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- First-Line Immunotherapy for Non–Small-Cell Lung Cancer
- (2022) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
- (2022) Mingjun Rui et al. JOURNAL OF MEDICAL ECONOMICS
- Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
- (2022) F. Cortiula et al. ANNALS OF ONCOLOGY
- Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
- (2022) Xiuting Mo et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
- (2022) Maria Polyzoi et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
- (2022) Malin Berling et al. JOURNAL OF MEDICAL ECONOMICS
- First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
- (2021) Zhiguang Yang et al. Expert Review of Pharmacoeconomics & Outcomes Research
- First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
- (2021) Ye Peng et al. ADVANCES IN THERAPY
- Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
- (2021) Francesco Spagnolo et al. BMC CANCER
- Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer
- (2021) P. Travis Courtney et al. JAMA Network Open
- Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
- (2021) Liting Wang et al. ADVANCES IN THERAPY
- Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
- (2021) Ye Peng et al. ADVANCES IN THERAPY
- Toward personalized treatment approaches for non-small-cell lung cancer
- (2021) Meina Wang et al. NATURE MEDICINE
- Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
- (2021) Meng‐Meng Teng et al. Cancer Medicine
- Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer
- (2021) Xuezhi Hao et al. Frontiers in Pharmacology
- Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
- (2021) Xiaomin Wan et al. Frontiers in Pharmacology
- Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
- (2021) Thitima Kongnakorn et al. PHARMACOECONOMICS
- Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency
- (2021) Gemma E. Shields et al. PHARMACOECONOMICS
- Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
- (2021) Andreas Kuznik et al. VALUE IN HEALTH
- First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
- (2021) Qiao Liu et al. Frontiers in Pharmacology
- Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
- (2021) Liu Qiao et al. Frontiers in Pharmacology
- Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
- (2021) Szu-Chun Yang et al. Frontiers in Oncology
- Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
- (2021) Guiyuan Xiang et al. Frontiers in Public Health
- Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
- (2021) Alyson Haslam et al. JAMA Network Open
- First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness
- (2021) M. Zhang et al. CLINICAL ONCOLOGY
- Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
- (2020) Steven D. Criss et al. PLoS One
- Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
- (2020) Ning Wan et al. Cancer Medicine
- Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- (2020) Dong Ding et al. ADVANCES IN THERAPY
- Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
- (2020) Mohamed Ismail Abdul Aziz et al. JOURNAL OF MEDICAL ECONOMICS
- Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
- (2020) Caroline Robert et al. Nature Reviews Clinical Oncology
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
- (2020) Shen Lin et al. International Journal of Clinical Pharmacy
- Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China
- (2020) Yuan Jiang et al. European Journal of Hospital Pharmacy-Science and Practice
- Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
- (2020) Na Li et al. Cancer Management and Research
- Cost–effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
- (2020) Jiahao Li et al. Immunotherapy
- Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
- (2020) Haiying Ding et al. PLoS One
- Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
- (2020) Huabin Hu et al. Frontiers in Oncology
- Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review
- (2020) William V. Padula et al. Applied Health Economics and Health Policy
- A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
- (2020) David J. Vanness et al. ANNALS OF INTERNAL MEDICINE
- Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
- (2019) Weiting Liao et al. JOURNAL OF MEDICAL ECONOMICS
- Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer
- (2019) G M Blumenthal et al. ANNALS OF ONCOLOGY
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
- (2019) Kexun Zhou et al. LUNG CANCER
- Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
- (2019) Min Huang et al. Immunotherapy
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
- (2019) Longjiang She et al. LUNG CANCER
- Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
- (2019) Xiaohui Zeng et al. BMJ Open
- Cost‐Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
- (2019) Xiuhua Weng et al. ONCOLOGY RESEARCH
- First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective
- (2018) Xiaohan Hu et al. LUNG CANCER
- Cost-Effectiveness Thresholds: the Past, the Present and the Future
- (2018) Praveen Thokala et al. PHARMACOECONOMICS
- Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
- (2018) Mina Georgieva et al. LUNG CANCER
- Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
- (2018) Christos Chouaid et al. LUNG CANCER
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- (2017) Min Huang et al. PHARMACOECONOMICS
- A systematic review of the cost and cost-effectiveness studies of proton radiotherapy
- (2016) Vivek Verma et al. CANCER
- Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment
- (2016) Jordan D. Lane et al. JAMA Oncology
- Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer
- (2015) Peter C. Lo et al. CANCER
- Thresholds for the cost–effectiveness of interventions: alternative approaches
- (2015) Elliot Marseille et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Meta-analysis as Evidence
- (2014) Jesse A. Berlin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Financial Conflicts of Interest in Economic Analyses in Oncology
- (2010) Sekwon Jang et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
- (2010) Sekwon Jang et al. BREAST CANCER RESEARCH AND TREATMENT
- Small Cell Lung Cancer
- (2009) Taimur Sher et al. MAYO CLINIC PROCEEDINGS
- Subgroups and Heterogeneity in Cost-Effectiveness Analysis
- (2008) Mark Sculpher PHARMACOECONOMICS
- Medication Compliance and Persistence: Terminology and Definitions
- (2007) Joyce A. Cramer et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More